Bibliografia UJ CM

1/7
David J. Straus, Monika Długosz-Danecka, Sergey Alekseev, Arpad Illes, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen M. Ansell, Anas Younes, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero-Torres, Andrea Gallamini.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma : 3-year update of the ECHELON-1 study.
Blood
2020 : Vol. 135, nr 10, s. 735-742, il., bibliogr. 19 poz., abstr.
Auto korespondencyjny: David J. Straus.
p-ISSN: 0006-4971
AZ
ORG
AIF
IF: 22.113
Adres url:
2/7
Franck Morschhauser, Herve Tilly, Aristeidis Chaidos, Pamela McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip Campbell, Vincent Ribrag, Gandhi Laurent Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles.
Tazemetostat for patients with relapsed or refractory follicular lymphoma : an open-label, single-arm, multicentre, phase 2 trial.
Lancet. Oncology
2020 : Vol. 21, nr 11, s. 1433-1442, il., bibliogr. 30 poz., sum.
Autor korespondencyjny: Franck Morschhauser.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 41.316
Adres url:
Streszczenie w PubMed:
3/7
Ajay K. Gopal, Stephen J. Schuster, Nathan H. Fowler, Judith Trotman, Georg Hess, Jing-Zhou Hou, Abdulraheem Yacoub, Michael Lill, Peter Martin, Umberto Vitolo, Andrew Spencer, John Radford, Wojciech Jurczak, James Morton, Dolores Caballero, Sanjay Deshpande, Gary J. Gartenberg, Shean-sheng Wang, Rajendra N. Damle, Michael Schaffer, Sriram Balasubramanian, Jessica Vermeulen, Bruce D. Cheson, Gilles Salles.
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Journal of Clinical Oncology
2018 : Vol. 36, nr 23, s. 2405-2412
Autor korespondencyjny: Ajay K. Gopal.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 28.245
Adres url:
Streszczenie w PubMed:
DOI:
4/7
Marek Trneny, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, Boris Afanasyev, Kamil Kaplanov, Antoine Thyss, Alexej Kuzmin, Sergey Voloshin, Kazimierz Kuliczkowski, Agnieszka Giza, Noel Milpied, Caterina Stelitano, Reinhard Marks, Lorenz Trumper, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Casadebaig Bravo, Luca Arcaini.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet. Oncology
2016 : Vol. 17, nr 3, s. 319-331, il., bibliogr. 28 poz., sum.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 33.900
Adres url:
Streszczenie w PubMed:
5/7
Michael L. Wang, Kristie A. Blum, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M. Beaupre, Simon Rule.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.
Blood
2015 : Vol. 126, nr 6, s. 739-745, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971
AZ
ORG
AIF
IF: 11.847
Adres url:
Streszczenie w PubMed:
6/7
Wojciech Jurczak, Simon Rule, Peter Martin, Rebecca Auer, Brad S. Kahl, Agnieszka Giza, Bożena Jachimczak, Ranjana H. Advani, Jorge Romaguera, Michael Williams, Jacqueline Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Jesse McGreivy, Fong Clow, Darrin M. Beaupre, Lori Kunkel, Andre Goy, Kristie A. Blum, Wiktor Jędrzejczak, Michael L. Wang.
Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza - wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore.
(Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma - Results of an International, Multicenter, Phase 2 Study of Ibrutinib (PCI-32765) - EHA Encore.)
Acta Haematologica Polonica
2013 : Vol. 44, nr 3, s. 314-318, il., bibliogr. 7 poz., abstr.
p-ISSN: 0001-5814
AP
ORG
KBN
Adres url:
DOI:
7/7
Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Bras S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Y. Chang, Darrin M. Beaupre, Lori A. Kunkel, Kristie A. Blum.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
New England Journal of Medicine
2013 : Vol. 369, nr 6, s. 507-516, il., bibliogr. 29 poz., abstr.
p-ISSN: 0028-4793
AZ
ORG
AIF
IF: 54.420
Adres url:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ